Pear Therapeutics and Novartis presented findings from their study exploring the use of digital therapies in addition to traditional treatment in patients with schizophrenia.
Laura Genn
Advertisement
Articles by Laura Genn
Advertisement
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Olezarsen (Tryngolza) for Severe Hypertriglyceridemia
2
Delgocitinib Approval Fills a Long-Standing Gap in Chronic Hand Eczema Treatment
3
Q&A: Cardiometabolic Care Cascade Failure Points, with Rishi Wadhera, MD, MPP, MPhil
4
Q&A: CKM Care, IRA Policy, and Specialty Silos, With Rishi Wadhera, MD, MPP, MPhil
5